(Date:11/6/2009)... Intarcia Therapeutics, Inc. deliv...S® continuous delivery of exenatide) program ...Annual Diabetes Technology Meeting in San Francisc...n/prnh/20050301/SFTU126LOGO ) ,, Continuous S...ers Plasma Glucose, HbA1c and Reduces Weight in a ...
(Date:11/5/2009)... 5 GenVec, Inc. (Nasdaq:... the third quarter ended September 30, 2009. GenVe...hare) for the three months ended September 30, 200...r share) in the comparable quarter of 2008. For th...et loss was $14.1 million ($0.15 per share), compa...
(Date:11/5/2009)...wswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulleti...er, President and CEO of Imagenetix, will be prese...RO Conference on Thursday, December 3rd, at 10:30 ...out LD MICRO ,, LD MICRO is a by-invitation onl...ued companies in the micro-cap space. Since 2002, ...
(Date:11/5/2009)...Newswire-FirstCall/ -- Transgenomic, Inc. (OTC Bul...ts for the quarter ended September 30, 2009. The C...bles that follow. ,, Third Quarter 2009 ,,....01 per share for the third quarter of 2009 as com... for the third quarter of 2008. ,, Net sales w...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7...harmaceuticals,a division of Wyeth (NYSE: WYE ), ...ments with Solvay Pharmaceuticals for the developm... other compounds in earlier,stages of development ...ther psychiatric conditions., Wyeth terminated th...portunity for bifeprunox and determining it would ...
...ng distributor of market,intelligence, MarketResea...hip with Spectra Intelligence which allows for the...ry market analyses through the,MarketResearch.com ...ofessionals throughout the world,easy access to co... from,research publications authored by market exp...
...ex, Inc.,(Nasdaq: MEDX ) announced today that it ...al Group Second Annual SIGnificant Investment Opti...dnesday, March 5, 2008, in New,York. The event wil...estor,Relations section of the Medarex website at ...he presentation will be available following the ev...
Other Biology Technology:Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds 2MarketResearch.com Announces Distribution of Spectra Intelligence Research 2Medarex to Present at the Susquehanna Financial Group Healthcare Conference 2BMP-2 ELISA Kit from R&D Systems
5x MONO-RABBIT POLY C'GATE DILUENT from AbD Serotec
Argarase from BioVision
SAMPLE DILUENTS BUFFER TRIAL PACK from AbD Serotec
Biology Products: